Skip to main content
Erschienen in: International Journal of Colorectal Disease 1/2010

01.01.2010 | Original Article

Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells

verfasst von: Kamal Yavari, Mohammad Taghikhani, Mohammad Ghannadi Maragheh, Seyed A. Mesbah-Namin, Mohammad Hossein Babaei

Erschienen in: International Journal of Colorectal Disease | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Colon cancer is the second leading cause of cancer death worldwide. Elevated expression of insulin-like growth factor-I receptor (IGF-IR) is a frequent genetic abnormality seen in this malignancy. For a better understanding of its role in maintaining the malignant phenotype, we used RNA interference (RNAi) directed against IGF-IR in our study. The aim of this study was to examine the anti-proliferation and chemosensitization effects elicited by a decrease in the transcription and protein levels of IGF-IR by RNAi in SW480 colon cancer cells.

Methods

A plasmid-based polymerase III promoter system was used to deliver and express short interfering RNA (siRNA) targeting IGF-IR to reduce its expression in SW480 cells. Western blot analysis was used to measure the protein level of IGF-IR. We assessed the effects of IGF-IR silencing on cancer cell growth by a cell growth curve. The effect of the 5-fluorouracil (5-FU)-induced cell death by knockdown of IGF-IR was also investigated by methyl thiazolyl tetrazolium assay.

Results

Transfection of siRNA targeting IGF-IR was shown to reduce IGF-IR messenger RNA levels by 95%. Western blotting detected a similar inhibition of IGF-IR protein levels in those cells. The cells transfected with PKD-short hairpin RNA-IGF-IR-V2 significantly decreased cell growth and rendered cells more sensitive to chemotherapy. The highest proliferation inhibitory and chemosensitization ratios were 53 ± 2% and 1.78, respectively.

Conclusion

This study indicates that downregulation of IGF-IR results in significant inhibition of tumor growth in vitro. It also provides a promising strategy to chemotherapy efficacy in human tumors and forming a basis for future in vivo trials.
Literatur
1.
Zurück zum Zitat Cohen SJ, Cohen RB, Meropol NJ (2005) Targeting signal transduction pathways in colorectal cancer—more than skin deep. J Clin Oncol 23:5374–5385CrossRefPubMed Cohen SJ, Cohen RB, Meropol NJ (2005) Targeting signal transduction pathways in colorectal cancer—more than skin deep. J Clin Oncol 23:5374–5385CrossRefPubMed
2.
3.
Zurück zum Zitat Labianca R, Beretta G, Gatta G, de Braud F, Wils J (2004) Colon cancer. Crit Rev Oncol Hematol 51:145–170CrossRefPubMed Labianca R, Beretta G, Gatta G, de Braud F, Wils J (2004) Colon cancer. Crit Rev Oncol Hematol 51:145–170CrossRefPubMed
4.
Zurück zum Zitat Ansari R, Mahdavinia M, Sadjadi A et al (2006) Incidence and age distribution of colorectal cancer in Iran. Results of a population-based cancer registry. Cancer Lett 240:143–147CrossRefPubMed Ansari R, Mahdavinia M, Sadjadi A et al (2006) Incidence and age distribution of colorectal cancer in Iran. Results of a population-based cancer registry. Cancer Lett 240:143–147CrossRefPubMed
5.
Zurück zum Zitat Grady WM (2005) Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 33:684–686CrossRefPubMed Grady WM (2005) Epigenetic events in the colorectum and in colon cancer. Biochem Soc Trans 33:684–686CrossRefPubMed
6.
Zurück zum Zitat Williams NS, Gaynor RB, Scoggin S et al (2003) Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays. Clin Cancer Res 9:931–946PubMed Williams NS, Gaynor RB, Scoggin S et al (2003) Identification and validation of genes involved in the pathogenesis of colorectal cancer using cDNA microarrays. Clin Cancer Res 9:931–946PubMed
7.
Zurück zum Zitat LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137PubMed LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137PubMed
8.
Zurück zum Zitat Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRefPubMed Yu H, Rohan T (2000) Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 92:1472–1489CrossRefPubMed
9.
Zurück zum Zitat Shoshana Y, Pnina LB (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420CrossRef Shoshana Y, Pnina LB (2005) The role of the growth hormone/insulin-like growth factor axis in tumor growth and progression: lessons from animal models. Cytokine Growth Factor Rev 16:407–420CrossRef
10.
Zurück zum Zitat Baker J, Liu JP, Robertson EJ, Efstratiadis A (1993) Role of insulin like growth factors in embryonic and postnatal growth. Cell 75:73–82PubMed Baker J, Liu JP, Robertson EJ, Efstratiadis A (1993) Role of insulin like growth factors in embryonic and postnatal growth. Cell 75:73–82PubMed
11.
Zurück zum Zitat Rosen CJ, Pollak M (1999) Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab 10:136–141CrossRefPubMed Rosen CJ, Pollak M (1999) Circulating IGF-I: new perspectives for a new century. Trends Endocrinol Metab 10:136–141CrossRefPubMed
12.
Zurück zum Zitat Guerreiro AS, Boller D, Doepfner KT, Arcaro A (2006) IGF-IR: potential role in antitumor agents. Drug News Perspect 19:261–272CrossRefPubMed Guerreiro AS, Boller D, Doepfner KT, Arcaro A (2006) IGF-IR: potential role in antitumor agents. Drug News Perspect 19:261–272CrossRefPubMed
13.
Zurück zum Zitat Sepp-Lorenzino L (1998) Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47:235–253CrossRefPubMed Sepp-Lorenzino L (1998) Structure and function of the insulin-like growth factor I receptor. Breast Cancer Res Treat 47:235–253CrossRefPubMed
14.
Zurück zum Zitat De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1:769–783CrossRefPubMed De Meyts P, Whittaker J (2002) Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 1:769–783CrossRefPubMed
15.
Zurück zum Zitat Samani AA, Yakar S, LeRoith D, Brodt P (2006) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47CrossRefPubMed Samani AA, Yakar S, LeRoith D, Brodt P (2006) The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 28:20–47CrossRefPubMed
16.
Zurück zum Zitat Valentinis B, Baserga R (2001) IGF-I receptor signalling in transformation and differentiation. Clin Mol Pathol 54:133–137CrossRef Valentinis B, Baserga R (2001) IGF-I receptor signalling in transformation and differentiation. Clin Mol Pathol 54:133–137CrossRef
17.
Zurück zum Zitat Favelyukis S, Till JH, Hubbard SR, Miller WT (2001) Structure and autoregulation of the insulin like growth factor I receptors. Nat Struct Biol 8:1058–1063CrossRefPubMed Favelyukis S, Till JH, Hubbard SR, Miller WT (2001) Structure and autoregulation of the insulin like growth factor I receptors. Nat Struct Biol 8:1058–1063CrossRefPubMed
18.
Zurück zum Zitat Monzavi R (2002) IGFs and IGFBPs roles in health and disease. Best Pract Res Clin Endocrinol Metab 16:437–447CrossRef Monzavi R (2002) IGFs and IGFBPs roles in health and disease. Best Pract Res Clin Endocrinol Metab 16:437–447CrossRef
19.
Zurück zum Zitat Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76:1005–1026PubMed Stewart CE, Rotwein P (1996) Growth, differentiation, and survival: multiple physiological functions for insulin-like growth factors. Physiol Rev 76:1005–1026PubMed
20.
Zurück zum Zitat Weber MM, Fottner C, Liu SB et al (2002) Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086–2095CrossRefPubMed Weber MM, Fottner C, Liu SB et al (2002) Overexpression of the insulin-like growth factor I receptor in human colon carcinomas. Cancer 95:2086–2095CrossRefPubMed
21.
Zurück zum Zitat Corinna B, Bernd G (2004) The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res 14:287–295CrossRef Corinna B, Bernd G (2004) The insulin like growth factor-1 receptor (IGF-1R) as a drug target: novel approaches to cancer therapy. Growth Horm IGF Res 14:287–295CrossRef
22.
Zurück zum Zitat Burtrum D, Zhu Z, Lu D et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921PubMed Burtrum D, Zhu Z, Lu D et al (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 63:8912–8921PubMed
23.
Zurück zum Zitat Sachdev D, Hartell JS, Lee AV (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279:5017–5024CrossRefPubMed Sachdev D, Hartell JS, Lee AV (2004) A dominant negative type I insulin-like growth factor receptor inhibits metastasis of human cancer cells. J Biol Chem 279:5017–5024CrossRefPubMed
24.
Zurück zum Zitat Chernicky CL, Tan L, Gan SU, Ilan J (2000) Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7:384–395CrossRefPubMed Chernicky CL, Tan L, Gan SU, Ilan J (2000) Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo. Cancer Gene Ther 7:384–395CrossRefPubMed
25.
Zurück zum Zitat Gudkov AV, Zelnick CR, Kazarov AR et al (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II—interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 90:3231–3235CrossRefPubMed Gudkov AV, Zelnick CR, Kazarov AR et al (1993) Isolation of genetic suppressor elements, inducing resistance to topoisomerase II—interactive cytotoxic drugs, from human topoisomerase II cDNA. Proc Natl Acad Sci U S A 90:3231–3235CrossRefPubMed
26.
Zurück zum Zitat Collins FS, Green ED, Guttmacher AE, Guyer MS (2002) A vision for the future of genomic research. Nature 422:835–847CrossRef Collins FS, Green ED, Guttmacher AE, Guyer MS (2002) A vision for the future of genomic research. Nature 422:835–847CrossRef
27.
Zurück zum Zitat Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31(12):3185–3193CrossRefPubMed Grünweller A, Wyszko E, Bieber B, Jahnel R, Erdmann VA, Kurreck J (2003) Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 31(12):3185–3193CrossRefPubMed
28.
Zurück zum Zitat Scherer LJ, Rossi JJ (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21:1457–1465CrossRefPubMed Scherer LJ, Rossi JJ (2003) Approaches for the sequence-specific knockdown of mRNA. Nat Biotechnol 21:1457–1465CrossRefPubMed
29.
Zurück zum Zitat Milhavet O, Gary DS, Mattson MP (2003) RNA Interference in biology and medicine. Pharmacol Rev 55:629–648CrossRefPubMed Milhavet O, Gary DS, Mattson MP (2003) RNA Interference in biology and medicine. Pharmacol Rev 55:629–648CrossRefPubMed
30.
Zurück zum Zitat Pfeffer S, Meister G, Landthaler M, Tuschl T (2005) RNA silencing. BIF Futura 20:83–90 Pfeffer S, Meister G, Landthaler M, Tuschl T (2005) RNA silencing. BIF Futura 20:83–90
31.
32.
Zurück zum Zitat Sumimoto H (2005) Use of RNA interference technology for specific gene silencing. Ann Cancer Res Ther 13:23–25 Sumimoto H (2005) Use of RNA interference technology for specific gene silencing. Ann Cancer Res Ther 13:23–25
33.
Zurück zum Zitat Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457–467CrossRefPubMed Dykxhoorn DM, Novina CD, Sharp PA (2003) Killing the messenger: short RNAs that silence gene expression. Nat Rev Mol Cell Biol 4:457–467CrossRefPubMed
34.
Zurück zum Zitat Barik S (2005) Silence of the transcripts: RNA interference in medicine. J Mol Med 83:764–773CrossRefPubMed Barik S (2005) Silence of the transcripts: RNA interference in medicine. J Mol Med 83:764–773CrossRefPubMed
35.
Zurück zum Zitat Friedrich I, Shir A, Klein S, Levitzki A (2004) RNA molecules as anti-cancer agents. Semin Cancer Biol 14:223–230CrossRefPubMed Friedrich I, Shir A, Klein S, Levitzki A (2004) RNA molecules as anti-cancer agents. Semin Cancer Biol 14:223–230CrossRefPubMed
36.
Zurück zum Zitat Masiero M, Nardo G, Indraccolo S, Favaro E (2007) RNA interference: implication for cancer treatment. Mol Aspects Med 28:143–166CrossRefPubMed Masiero M, Nardo G, Indraccolo S, Favaro E (2007) RNA interference: implication for cancer treatment. Mol Aspects Med 28:143–166CrossRefPubMed
37.
Zurück zum Zitat Chung-Faye GA, Kerr DJ (2000) Innovative treatment for colon cancer. Br Med J 321(2):1397–1399CrossRef Chung-Faye GA, Kerr DJ (2000) Innovative treatment for colon cancer. Br Med J 321(2):1397–1399CrossRef
38.
Zurück zum Zitat LeRoith D, Werner H, Beitner JD, Roberts CT (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143–163PubMed LeRoith D, Werner H, Beitner JD, Roberts CT (1995) Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 16:143–163PubMed
39.
40.
Zurück zum Zitat Bantounas I, Phylactou LA, Uney JB (2004) RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33:545–557CrossRefPubMed Bantounas I, Phylactou LA, Uney JB (2004) RNA interference and the use of small interfering RNA to study gene function in mammalian systems. J Mol Endocrinol 33:545–557CrossRefPubMed
41.
Zurück zum Zitat Nagy P, Arndt-Jovin DJ, Jovin TM (2003) Small interferencing RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 285:39–49CrossRefPubMed Nagy P, Arndt-Jovin DJ, Jovin TM (2003) Small interferencing RNAs suppress the expression of endogenous and GFP-fused epidermal growth factor receptor and induce apoptosis in erbB1-overexpressing cells. Exp Cell Res 285:39–49CrossRefPubMed
42.
Zurück zum Zitat Sui G, Soohoo C, Affarel BB et al (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 99:5515CrossRefPubMed Sui G, Soohoo C, Affarel BB et al (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc Natl Acad Sci U S A 99:5515CrossRefPubMed
43.
Zurück zum Zitat Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nature 5:355–365 Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nature 5:355–365
44.
Zurück zum Zitat Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20:500–505CrossRef Tuschl T (2002) Expanding small RNA interference. Nat Biotechnol 20:500–505CrossRef
45.
Zurück zum Zitat Kaykas A, Moon RT (2004) A plasmid-based system for expressing small interfering RNA libraries in mammalian cells. BMC Cell Biol 5:1–11CrossRef Kaykas A, Moon RT (2004) A plasmid-based system for expressing small interfering RNA libraries in mammalian cells. BMC Cell Biol 5:1–11CrossRef
46.
Zurück zum Zitat Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553CrossRefPubMed Brummelkamp TR, Bernards R, Agami R (2002) A system for stable expression of short interfering RNAs in mammalian cells. Science 296:550–553CrossRefPubMed
Metadaten
Titel
Downregulation of IGF-IR expression by RNAi inhibits proliferation and enhances chemosensitization of human colon cancer cells
verfasst von
Kamal Yavari
Mohammad Taghikhani
Mohammad Ghannadi Maragheh
Seyed A. Mesbah-Namin
Mohammad Hossein Babaei
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
International Journal of Colorectal Disease / Ausgabe 1/2010
Print ISSN: 0179-1958
Elektronische ISSN: 1432-1262
DOI
https://doi.org/10.1007/s00384-009-0783-2

Weitere Artikel der Ausgabe 1/2010

International Journal of Colorectal Disease 1/2010 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.